Prasinezumab clinical trials
Prasinezumab is named as an intervention in 4 current clinical trials in our France, Spain, USA, Germany, Italy, Austria, UK, Poland, Canada, China, Denmark, Portugal, Brazil, Mexico, South Korea, Taiwan, Australia, Israel and Sweden registers. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Hoffmann-La Roche (3). The most-studied condition is Parkinson's Disease. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
How Prasinezumab works
All drug targets →- Alpha-synuclein binding agent Binding agentTarget: SNCA synuclein alpha✓ In ChEMBL and the Guide to Pharmacology
- Parkinson diseasePhase 3
- Mental deteriorationPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4298077, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 13330, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Prasinezumab
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Prasinezumab
4 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Prasinezumab in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Prasinezumab. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A randomized, double-blind, placebo-controlled, 104-week proof-of-concept study to evaluate the efficacy of intravenous prasinezumab in participants with Parkinson's disease carrying a severe mutation in the GBA gene (prevent cognitive decline in GBA-associated PD)
2024-513496-40-00 · Nervous System Diseases
|
Phase 2 | Ongoing | Universitaetsklinikum Tuebingen AöR | Spain, Germany, Italy + 3 more |
Conditions studied with Prasinezumab
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Hoffmann-La Roche | 3 |
| University Hospital Tuebingen | 1 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Prasinezumab trials
How many clinical trials are testing Prasinezumab?
4 current trials in our France, Spain, USA, Germany, Italy, Austria, UK, Poland, Canada, China, Denmark, Portugal, Brazil, Mexico, South Korea, Taiwan, Australia, Israel and Sweden registers name Prasinezumab (also registered as RO7046015) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Prasinezumab trials recruiting patients?
Yes. 2 of the 4 trials are recruiting: 2 with sites in France, 2 with sites in Spain, 1 with sites in USA, 2 with sites in Germany, 2 with sites in Italy, 1 with sites in Austria, 1 with sites in UK, 1 with sites in Poland, 1 with sites in Canada, 1 with sites in China, 1 with sites in Denmark, 1 with sites in Portugal, 1 with sites in Brazil, 1 with sites in Mexico, 1 with sites in South Korea, 1 with sites in Taiwan, 1 with sites in Australia and 1 with sites in Sweden. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Prasinezumab clinical trials?
Hoffmann-La Roche (3) and University Hospital Tuebingen (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Prasinezumab works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Prasinezumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Prasinezumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.